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Volume 51, Number 6 Abstracts 1585a graft configurationwas 50% in their series (2 of 4). The authors postulate that
the well-known tendency for Dacron to dilate over time may be accentuated
by the presence of an endograft. They suggest oversizing the endograft 20%
and a proximal landing zone with at least 4 cm of overlap when the graft is
landed in Dacron.
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous
Thromboembolism Prevention Trials
Eikelboom JW,QuinlanDJ, O’Donnell M. Circulation 2009;120:2006-11.
Conclusion: Major bleeding in hospitalized patients participating in
venous thromboembolism (VTE) prevention trials is a strong predictor of
mortality.
Summary: Emerging evidence suggests bleeding is a strong predictor
of death in patients with acute arterial thrombosis receiving antithrombotic
therapy (Eur Heart 2007;28:1193-204; Neurology 2008;71:650-5). It is,
however, unknown whether a similar association exists between bleeding
and death in patients with VTE. The authors used a fondaparinux VTE
prevention database to explore associations between major bleeding and
death, with adjustments for other patient characteristics. Analysis of the
fondaparinux database was provided by GlaxoSmithKline. The database
consisted of all phase 3 randomized controlled trials comparing fondapa-
rinux (2.5 mg once daily) with low- molecular-weight heparin or placebo for
prevention of VTE. The trials included 13,085 patients undergoing hip
replacement surgery, major knee surgery, or elective abdominal surgery, and
also high-risk medical patients. Major bleeding was defined as retroperito-
neal, intracranial, or intraspinal bleeding; any bleeding that involved a critical
organ or led to reoperation, or overt bleeding with a bleeding index
(calculated as the number of packed red blood cells or whole blood trans-
fusions plus pre- bleeding hemoglobin concentration minus post bleeding
hemoglobin concentration)2. The primary outcome variable was death in
30 days.
Patients who developed major bleeding were older, more likely to be
male, had a lower body mass index and lower creatinine clearance, and were
more likely to be receiving fondaparinux. At 30 days, the risk of death was
sevenfold higher among patients with a major bleeding event (8.6% vs 1.7%;
adjusted hazard ratio [HR], 6.96; 95% confidence interval [CI], 4.6-10.5).
However, fondaparinux was associated with a decreased mortality rate in the
patients experiencing major bleeding (6.8% vs 11.4%; HR, 0.58; 95% CI,
0.27-1.23).
Comment: This article has three findings of particular interest. First,
lower body weight, male sex, and renal dysfunction are predictors of major
bleeding in patients enrolled in VTE prevention trials. Second, major
bleeding in patients enrolled in these trials is associated with a sevenfold
increased mortality rate at 30 days. Finally, fondaparinux, although associ-
ated with an increased risk of bleeding, appeared to be associated with a
decreased risk of death with major bleeding compared with major bleeding
associated with other antithrombotic agents. The data are consistent with
previous studies showing an association between major bleeding and death
in patients treated with antithrombotic agents for acute coronary syndromes
and ischemic stroke. Only 6% of the deaths in this analysis were directly
attributed to the bleeding episode. The precise reasons for increased death in
patients who develop major bleeding while being treated with anticoagula-
tion agents remain to be determined.
Open Abdominal Aortic Aneurysm Repair in the Endovascular Era:
Effect of Clamp Site on Outcomes
Landry G, Lau I, Liem T, et al. Arch Surg 2009;144:811-6.
Conclusion: Suprarenal cross clamping during open abdominal aortic
aneurysm (AAA) repair is associated with increased rates of complications
but similar mortality rates and need for nursing home placement as open
abdominal aortic aneurysm (AAA) repair with infrarenal clamping.
Summary: Currently, the most frequent anatomic restriction for use of
the endovascular aneurysm repair (EVAR) is an inadequate infrarenal neck
to achieve proximal fixation. Although performed “under the table” in some
centers, in only a few centers in the United States is fenestrated endografting
currently performed with actual investigational device exemptions (IDEs).
Therefore, AAAs with an inadequate proximal fixation zone still need open
AAA repair in most centers. This is a study of contemporary series of open
AAA repairs in patients who were not considered suitable candidates for
EVAR.
Patients were derived from those undergoing open repair during the
endovascular era. Consecutive nonruptured open aneurysm repairs from
March 1, 2000, through July 31, 2007, were reviewed. There were 185
patients who underwent 103 infrarenal and 82 suprarenal cross-clamp
repairs. The occurrence of any complication was 37%with infrarenal and 61%
for suprarenal cross-clamp repairs (P  .001). The 30-day mortality was
2.9% for AAA repair with an infrarenal cross clamp and 6.1% for AAA repair
with a suprarenal cross clamp (P  .18). Complications that occurred most
frequently in the suprarenal cross-clamp group were postoperative renal
insufficiency and pulmonary complications. Suprarenal cross clamps werealso associated with greater intraoperative blood loss, operative duration,
and use of adjunctive renal or visceral grafts. Intensive care units and hospital
lengths of stay were also longer in the suprarenal cross-clamp group. Patients
undergoing suprarenal cross clamp had a 25.6% rate of temporary nursing
home placement vs 17.5% in those patients treated with an infrarenal cross
clamp (P  .14).
Comment: At some point it is almost inevitable that open AAA surgery
will, for the most part, be relegated to the to the dust bin. When this actually
happens will depend on a slew of regulatory, engineering, technical, and cost
considerations. In the interim, some AAAs will still need to be repaired with
open techniques. The data indicate what is well known: Open repair is
associated with significant morbidity, but mortality rates are low. Open
repairs of AAA are, at the same time, becoming more infrequent and more
complex.With the limited training available in these complex repairs inmany
vascular surgical residencies, it may not be appropriate for most finishing
vascular surgical trainees to perform open AAA repair right out of residency
without senior colleague supervision. On the other hand, it is also very likely
not to be appropriate for older vascular surgeons to perform fenestrated
endografts without junior colleague supervision!
Quality of Life in Patients with Idiopathic Subclavian Vein Thrombosis
Berzaczy D, Popovic M, Reiter M, et al. Thromb Res 2010:125:25-8.
Conclusion: Patients with idiopathic subclavian vein thrombosis treated
without surgical or catheter based intervention have good overall quality of
life and deal well with their physical limitations.
Summary: Late clinical manifestations of axillosubclavian vein throm-
bosis can be persistent swelling and the presence of prominent veins on the
chest wall in 7% to 46% of patients (Thromb Res 2005;117:609-14). The
authors sought to determine how quality of life was affected after idiopathic
subclavian vein thrombosis using the Short Form (SF)-36 survey and the
Disabilities of the Arm, Shoulder and Hand (DASH) outcome question-
naire. The DASH, which was introduced in 1994 by the American Academy
of Orthopedic surgeons, is a self-administered questionnaire of 30 questions
designed to measure upper extremity disability and symptoms. It appears to
be an accurate measure of disability irrespective of underlying cause (J Hand
Therapy 2001;14:128-46). The intent was to assess thrombosis-related
disability of the upper extremity and general quality of life in patients who
had had axillosubclavian vein thrombosis. The DASH and SF-36 both use
100-point scales. In DASH, 0 represents uncompromised function and 100
is maximum limitation; whereas in the SF36, 0 is the lowest rating quality of
life and 100 indicates the best imaginable quality of life.
The patients had been treated with anticoagulation alone or systemic
thrombolysis, followed by anticoagulation. They did not appear to be
treated with catheter-directed thrombolysis or surgical decompression of the
thoracic outlet. Mean follow up was 120  80 months. Right-sided subcla-
vian vein thrombosis occurred in 22 patients (60%) and left-sided subclavian
vein thrombosis occurred in 14 (40%). Anticoagulant therapy was used for
12 months after initial presentation in 92% and for12 months in 8%. At
follow-up, arm swelling was present in 43% of patients, venous ectasias in
54%, pain at rest in 16%, and pain with exercise in 22%. Despite these
findings, mean DASH and SF-36 scores were good, with a mean DASH
score of 10.7  12 and mean scores for the SF-36 physical component
summary and mental component system of 52  9.3 and 46  9.5,
respectively.
Comment: These data provide long-term information on symptoms
and signs after conservatively managed idiopathic axillosubclavian vein
thrombosis and the effects of these signs and symptoms on patient-perceived
function and quality of life. Advocates of invasive management of subclavian
vein thrombosis will point to the high prevalence of late symptoms and signs
related to the subclavian vein thrombosis. Those favoring more conservative
management will note, despite the presence of arm swelling and symptoms,
the patients actually had little functional impairment and a very reasonable
quality of life. In either case, the data suggest it may be difficult to demon-
strate significant patient-perceived improvement with surgical therapy over
medical management alone in patients with axillosubclavian vein thrombo-
sis.
The General Prognosis of Patients with Peripheral Arterial Disease
Differs According to the Disease Localization
Aboyans V, Desormais I, Lacroix P, et al. J Am Coll Cardiol 2010;55:898-
903.
Conclusion: Independent of risk factors and other comorbidities, in
patients with peripheral arterial disease (PAD), there is a poorer overall
general prognosis in patients with proximal (aortoiliac) disease compared
with those with more distal PAD.
Summary: Cardiovascular risk factors, socioeconomic, and demo-
graphic differences are associated with different patterns of peripheral arterial
disease (PAD) and progression rates of PAD differ between large and small
vessels. Distal PAD is associated with more adverse outcomes with respect to
the limb itself. The general belief, with little direct evidence, is also that more
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therefore sought to determine, through retrospective analysis of arterio-
grams, whether the general prognosis of PAD patients differs according to
location of disease.
Patients who underwent a first digital subtraction arteriogram of the
lower limbs at the authors’ institution between January 2000 and December
2005 were reviewed. Arterial stenoses 50% in diameter reduction were
scored by two senior physicians. Up until April 2007, death, nonfatal
myocardial infarction, stroke, and coronary and carotid revascularization
were recorded. The primary outcome variable included all these events.
There were 400 PAD patients (75% male), with a mean age of 68.3 
12.3 years, who met qualifications for the study. Iliac disease was noted in
211 (52.8%) and infrainguinal disease in 344 (86.0%). Proximal PAD was
associated with greater prevalence of male sex and smoking, whereas more
distal PAD was associated with older-age diabetes, hypertension, and renal
failure (P .05). Follow up averaged 34 23months. After adjustments for
age, sex, cardiovascular disease history and cardiovascular disease risk factors,
critical leg ischemia status and treatments, event and survival curves differed
according to PAD location (P .03). Proximal PADwas associated with the
worst prognosis, with a primary outcome hazard ratio of 3.28 and a death
hazard ratio of 3.18 (P  .002 vs distal PAD).
Comment: This is the first study to report a poorer overall prognosis in
patients with aortoiliac disease compared with those with more distal PAD.
An obvious limitation of this study is that only patients undergoing angiog-
raphy were included. The information was therefore primarily derived from
patients with severe vascular disease where some form of intervention was
contemplated. The results of this study need to be confirmed in a more
general population of patients with PAD. However, if these findings are
confirmed, it could result in potential additional risk stratification of PAD
patients according to which lower extremity arteries are affected.
Two-Stage Basilic Vein Transposition—A New Approach for Pediatric
Dialysis Access
Kim AC, McLean S, Swearingen AM, et al. J Ped Surg 2010;45:177-84.
Conclusion: Rates of arteriovenous fistula (AVF) maturation and
patency in pediatric patients are higher for two-stage basilic vein transposi-
tion (BVT) than for BVT performed in one stage.Summary: BVT can be performed as a one-stage or a two-stage
procedure. Advantages of a two-stage procedure are potential maturation of
smaller veins before the actual transposition, thereby potentially improving
ultimate success of the transposition. The two-stage procedure is technically
easier than a one-stage transposition but does involve two separate proce-
dures. The authors sought to determine whether using two-stage BVTs in
children improves fistula maturation rates, fistula use, and overall patency
compared with one-stage BVTs, other types of AVFs, and AV grafts. The
study took place at two tertiary care children’s hospitals. Between 1997 and
2008, 31 patients underwent AV access creation. Forty-two access proce-
dures were performed: 15 two-stage BVTs (36%), 13 one-stage BVTs (31%),
6 radiocephalic fistulas (14%), 3 brachiocephalic fistulas (7%), 1 brachiobra-
chial fistula (2%), and 4 AV grafts (10%). Average follow-up was 20.4 3.2
months for two-stage BVT and 47.9  4.1 months for other AVFs. All
two-stage BVTsmatured, but only 14 of 27 (52%) other AVFsmatured (P
.001). More two-stage BVTs (87%) were used for dialysis than other AVFs
(48%; P  .024). The fistula failure rate in the two-stage BVT was 7%
compared with 59% for other AVFs (P  .001). The patency at 1-year was
91% for two-stage BVT vs 47% for other AVFs (P  .003). The size of the
basilic vein increased from 0.3  0.027 cm before the performance of the
first stage of the BVT to 0.79 0.08 cm after the first stage of the two-stage
BVT. Of the 16 failures in the other AVF group, 11 were primary failures
occurring before attempted access. One case of steal syndrome occurred in
the two-stage BVT group.
Comment: Establishing durable hemodialysis access is difficult in all
patients and is particularly difficult in the pediatric population because of the
overall small caliber of the vessels. Most of the patients in this study,
however, were not small children but adolescents with reasonable size vessels
to work with. It is therefore a bit unclear whether the apparent advantage of
the two-stage BVT in these patients was due to converting a more difficult
procedure to a less difficult procedure for performance by surgeons who do
not perform large volumes of dialysis access surgery. Two-stage BVT re-
quires two operations, but the first is a relatively small procedure. Given the
big picture, there appears to be no great disadvantage to the two-stage
procedure and there may be a significant advantage in pediatric patients. The
authors’ contention that two-stage BVT should be preferred hemodialysis
access in the pediatric population deserves consideration.
